May 16, 2025

FDA Approves PD-1–Targeted Monoclonal Antibody for SCAC

The FDA has approved Zynyz (retifanlimab-dlwr) as the first programmed death receptor-1 inhibitor for first-line treatment of advanced squamous cell carcinoma of the anal canal.

Conexiant

May 16, 2025

Long-Term Data Support BCT for BRCA-Mutated Breast Cancer

Researchers found that breast-conserving treatment provided long-term survival outcomes comparable to mastectomy in patients with breast cancer and BRCA1 or BRCA2 pathogenic variants.

Conexiant

May 16, 2025

Delandistrogene Moxeparvovec: Efficacy Evidence Questioned

The AAN Guidelines Subcommittee review finds delandistrogene moxeparvovec for DMD failed to meet primary functional outcomes despite FDA approval.

Conexiant

May 15, 2025

Assistant Professor Salary Gaps Persist Nationwide

Persistent salary disparities by gender, race, and ethnicity were identified among more than 45,000 U.S. assistant professors, with underrepresented in medicine women learning the least across all specialties.

Conexiant

May 14, 2025

Oral Option Now Available for PPGL

The FDA approved belzutifan as the first oral therapy for advanced pheochromocytoma and paraganglioma in patients aged 12 years and older.

Conexiant

May 13, 2025

Final Overall Survival Data: Amivantamab-vmjw Plus Lazertinib vs Osimertinib in EGFR-Mutated Non–Small Cell Lung Cancer

The phase III MARIPOSA trial was a head-to-head comparison of the EGFR tyrosine kinase inhibitor osimertinib and the combination of the bispecific EGF receptor–directed and MET receptor–directed mono...

The ASCO Post

May 13, 2025

Several Trials Show Clinical Activity With Osimertinib in Advanced EGFR-Mutant Non–Small Cell Lung Cancer

Updates from several clinical trials of the EGFR tyrosine kinase inhibitor osimertinib across stages and settings of EGFR-mutated non–small cell lung cancer (NSCLC) were presented at the European Lun...

The ASCO Post

May 13, 2025

GLP-1s May Protect Against Obesity-Related Cancer

First-generation GLP-1 receptor agonists provide comparable protection against obesity-related cancers as bariatric surgery.

Conexiant

May 12, 2025

Yearly Blood Tests May Cut Cancer Deaths by 21%

A state-transition model demonstrates that multicancer early detection blood tests significantly reduce late-stage cancer diagnoses and mortality, with annual screening intervals showing superior outcomes compared to biennial testing.

Conexiant